A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

In a prospective, open-label, single-center study, the effects of 10-yr GH replacement were determined.

Eighty-seven consecutive patients (52 men and 35 women), with a mean age of 44.1 (range 22-74) yr with adult-onset GH deficiency (GHD) were included.

Why It Was Studied

Only a few studies have investigated the effects of GH replacement in adults for more than 5 yr.

Who Took Part

The abstract describes 52 men taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as open-label.

Everyone knew when Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Cholesterol, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I, Lipoproteins and Sex Characteristics.

What This Means in Plain Language

The paper is an open-label study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 52 men.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.